| | 
Part, Chapter, Paragraph
1 I, 2. 10. 3(6) | Session 2006, Report I (C). ILO, Geneva.~
2 I, 2. 10. 3(7) | Freeman C, Soete L, Efendioglu U (
3 I, 2. 11 | Available at: htt df~Freeman C, Soete L, Efendioglu U (
4 I, 2. 11 | Session 2006, Report I (C): ILO, Geneva~Marrone S (
5 I, 2. 11 | Jun;66(3):188-98.~Medina c. et al. (2007): Nanoparticles:
6 II, 4. 3 | COM(2005): 24.~ ~Jagger, C. and EHEMU Team (2005):
7 II, 4. 3 | and Welfare.~ ~Riley, J. C. (1990): The risk of being
8 II, 4. 3 | 432.~ ~Robine, J.-M. and C. Jagger (2007): Healthy
9 II, 4. 3 | 328.~ ~Robine, J.-M. and C. Jagger (2007): Strategic
10 II, 4. 3 | Inserm~ ~Robine, J.-M., C. Jagger, et al. (2002):
11 II, 4. 3 | 119-133.~ ~Robine, J.-M., C. Jagger, et al. (2003):
12 II, 4. 3 | 6-14.~ ~Robine, J.-M., C. Jagger, et al., Eds. (2003):
13 II, 4. 3 | Sons.~ ~Robine J-M, Jagger C, and the Euro-REVES Group (
14 II, 4. 3 | 13:6-14.~ ~Robine, J.-M., C. Jagger, et al. (2001):
15 II, 5. 1. 1 | hyperphosphatemia, high plasma C Reactive Protein and Fibrinogen,
16 II, 5. 1. 1 | disease, i.e., hepatitis B and C virus (HBV and HCV) infection
17 II, 5. 2. 6 | morbidity and mortality (Baigent C et al, 2005). The available
18 II, 5. 2. 6 | found in 5.2.7)~Baigent C, Keech A, Kearney PM, Blackwell
19 II, 5. 2. 6 | Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto
20 II, 5. 2. 6 | 1571-1576.~Keys A, Aravanis C, Blackburn HW, Van Buchem
21 II, 5. 2. 7 | Palmieri L, Donfrancesco C, Giampaoli S, Trojani M,
22 II, 5. 2. 7 | Palmieri L, Donfrancesco C, Vanuzzo D, Chiodini P,
23 II, 5. 2. 7 | Heart J 18: 1231–48.~Sarti C, Stegmayr B, Tolonen H,
24 II, 5. 3. 9 | Sant M, Storm H, Allemani C, Ciccolallo L, Santaquilani
25 II, 5. 3. 9 | G, Capocaccia R, Stiller C, Kaatsch P, Berrino F, Terenziani
26 II, 5. 3. 9 | Capocaccia R, Martinez C, Mugno E, Coebergh JW, Baili
27 II, 5. 4. 8 | diabetes. The EURODIAB Subarea C Study Group Epidemiology.;
28 II, 5. 4. 8 | Pruna A, Ionescu-Tirgoviste C. (2002), A networked electronic
29 II, 5. 5.Int(15)| Delespaul P, Fuhrer R, Hooijer C, Lawlor BA, Kivela S-L,
30 II, 5. 5.Int(15)| Roelands M, Skoog I, Turrina C, deVries MW, Wilson KCM (
31 II, 5. 5. 1 | 76.~ ~Kessler R, Nelson C, McGonagle K, Liu G (1996):
32 II, 5. 5. 1 | Haro JM, Sevilla-Dedieu C, the ESEMeD/MHEDEA 2000
33 II, 5. 5. 2 | Eastern Europe (Regions B and C)23. ~ ~Apart from the methodological
34 II, 5. 5. 2(23)| and Turkey and the EURO C category, those with a high
35 II, 5. 5. 2 | Godfrey M, Townsend J, Surr C, Boyle G and Brooker D (
36 II, 5. 5. 3 | R.G, Sjöström M, Hillger C, Neumann G, Kirch W (in
37 II, 5. 5. 3 | D.; Lohr, K. N.; Bulik, C. M. (2007): Outcomes of
38 II, 5. 5. 3 | Gonzalez-Gross M, Leclercq C, Kafatos A, Molnar D, Marcos
39 II, 5. 5. 3 | K, Manios Y, Breidenasse C, Kersting M, Moreno LA,
40 II, 5. 5. 3 | A Miller, K.K, Almazan, C, Worley, M,. Soyka, L.A,
41 II, 5. 5. 3 | Sandersson K, Corry J, Issakidis C, Lapsley H (2003): Cost-effectiveness
42 II, 5. 5. 3 | Psychiatry 171:502-8.~Buizza C, Schulze B, Bertocchi E,
43 II, 5. 5. 3 | Medina-Mora ME, Borges G, Lara C, de Graaf R, Ormel J, Gureje
44 II, 5. 5. 3 | Bromet EJ, Gluzman S, Webb C, Kessler RC, Merikangas
45 II, 5. 5. 3 | Parsch JR, Ebenbichler C (2006): Antipsychotic drug-induced
46 II, 5. 5. 3 | 229-30.~Holt RI, Bushe C, Citrome L (2005): Diabetes
47 II, 5. 5. 3 | Leucht S, Stiegler M, Rummel C, Wahlbeck K, Kissling W (
48 II, 5. 5. 3 | Geddes J, Orbach G, Morgan C (2002): Psychological treatments
49 II, 5. 5. 3 | Jacoby A, Gorry J, Gamble C, Baker GA (2004): Public
50 II, 5. 5. 3 | 672.~Vignatelli L, Tonon C, D’Alessandro R, on behalf
51 II, 5. 5. 3 | benign and/or early cases; (c) the different degree of
52 II, 5. 5. 3 | continuing progression; (c) secondary-progressive MS (
53 II, 5. 5. 3 | 115-122.~Bencsik K, Rajda C, Füvesi J, et al (2001):
54 II, 5. 5. 3 | Neurol 8:463-469.~Confavreux C, Compston DA, Hommes OR,
55 II, 5. 5. 3 | Psychiatr 55:671–676.~Confavreux C (1994): Establishment and
56 II, 5. 5. 3 | suppl):S136–S139.~Confavreux C, Vukusic S, Moreau T, et
57 II, 5. 5. 3 | 343:1430–1438.~Confavreux C, Vukusic S, Adeleine P (
58 II, 5. 5. 3 | Scler 7:111-117.~McGuigan C, McCarthy A, Quigley C,
59 II, 5. 5. 3 | McGuigan C, McCarthy A, Quigley C, et al (2004): Latitudinal
60 II, 5. 5. 3 | Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker
61 II, 5. 5. 3 | Neuroepidemiology 5:71-79.~Pritchard C, Baldwin D, Mayers A (2004).
62 II, 5. 5. 3 | 170-174.~Totaro R, Marini C, Cialfi A, et al (2000):
63 II, 5. 5. 3 | Gosselin S, Confavreux C (2007): Regional variations
64 II, 5. 5. 3 | 13(4):626-632.~Anderson C, Checkoway H, Franklin GM,
65 II, 5. 5. 3 | de Munain A, Sarasqueta C, de Arce A, Poza JJ, Marti-Masso
66 II, 5. 5. 3 | M, Poskanzer DC, Rolland C, Miller H (1966): Neurological
67 II, 5. 5. 3 | 147-151.~Chio A, Magnani C, Schiffer D (1998): Prevalence
68 II, 5. 5. 3 | Perez-Sempere A, Cabezas C, Rodriguez F, de Pedro-Cuesta
69 II, 5. 5. 3 | 2146.~de Rijk MC, Tzourio C, Breteler MM, Dartigues
70 II, 5. 5. 3 | 128.~Elbaz A, Tranchant C (2007): Epidemiologic studies
71 II, 5. 5. 3 | Errea JM, Ara JR, Aibar C, de Pedro-Cuesta J (1999):
72 II, 5. 5. 3 | Bain PG, Baker M, Beech C, Bowman C, Holmes J, Kingdom
73 II, 5. 5. 3 | Baker M, Beech C, Bowman C, Holmes J, Kingdom WK, MacMahon
74 II, 5. 5. 3 | Poewe W, Rascol O, Sampaio C (2006): Review of the therapeutic
75 II, 5. 5. 3 | Disord 8(5):297-309.~LePen C, Wait S, Moutard-Martin
76 II, 5. 5. 3 | Ben-Shlomo Y, Lees A, Rooney C, Burn D (2005): Population
77 II, 5. 5. 3 | Riederer P, Trenkwalder C, Dodel R, Wittchen HU (2008):
78 II, 5. 5. 3 | D, Perkins KS, Counsell C (2003): Systematic review
79 II, 5. 5. 3 | Wick R, Botzel K, Sampaio C, Poewe W, Oertel W, Siebert
80 II, 5. 6. 6 | Ejlertsson G, Leden I, Rosenberg C (1993): Chronic pain in
81 II, 5. 6. 6 | Combe B, Landewe R, Lukas C, Bolosiu HD, Breedveld F,
82 II, 5. 6. 6 | Rheum Dis 66(1):34-45~Cooper C (1997): The crippling consequences
83 II, 5. 6. 6 | J Med 103:12S-17S~Cooper C, Atkinson EJ, Jacobsen SJ,
84 II, 5. 6. 6 | Epidemiol 137:1001-1005~Cooper C, Melton LJ, III (1992):
85 II, 5. 6. 6 | Coggon D, Cruddas M, Cooper C (1992): Osteoarthritis of
86 II, 5. 6. 6 | Redlund-Johnell I, Petterson C, De Laet C, Jonsson B (2004):
87 II, 5. 6. 6 | I, Petterson C, De Laet C, Jonsson B (2004): Mortality
88 II, 5. 6. 6 | Johnell O, Oden A, De Laet C, Jonsson B, Dawson A (2002):
89 II, 5. 6. 6 | Oden A, Jonsson B, De Laet C, Dawson A (2000): Risk of
90 II, 5. 6. 6 | Epidemiol 111:87-98~Lock C, Allgar V, Jones K, Marples
91 II, 5. 6. 6 | Jones K, Marples G, Chandler C, Dawson P (1999): Prevalence
92 II, 5. 6. 6 | Minshall ME, Shen W, Cooper C, Kanis J (2000): Health-related
93 II, 5. 6. 6 | 27-48~O'Neill TW, Cooper C, Finn JD, Lunt M, Purdie
94 II, 5. 6. 6 | Walsh K, Bendall H, Cooper C, Coggon D (2000) Back pain
95 II, 5. 6. 6 | 835-843~Symmons D, Mathers C, and Pfleger B (2003): Global
96 II, 5. 6. 6 | EM, Leufkens HG, Cooper C (2001): Epidemiology of
97 II, 5. 6. 6 | Mosby-Elsevier; Section C, Chapter 1.~Zollman C, Vickers
98 II, 5. 6. 6 | Section C, Chapter 1.~Zollman C, Vickers A (1999): ABC of
99 II, 5. 7. 4 | hyperphosphatemia, high plasma C Reactive Protein and Fibrinogen,
100 II, 5. 7. 7 | Asselbergs FW, Boersma C, de Vries R, Hillege HL,
101 II, 5. 7. 7 | 2006;28:432-44.~Baigent C, Burbury K, Wheeler D (2000):
102 II, 5. 7. 7 | M, Zanchetti A, Lombardi C, De Santo NG (2006): Low
103 II, 5. 7. 7 | 678-80.~Jager KJ, Zoccali C (2007): Clinical databases
104 II, 5. 7. 7 | 21(7):1899-905.~Meisinger C, Doring A, Lowel H (2006):
105 II, 5. 7. 7 | Culleton B, House A, Rabbat C, Fok M, et al (2006): Chronic
106 II, 5. 8. 7 | Henneberger P, Kreiss K, Mapp C, Milton D, Schwartz D, Toren
107 II, 5. 8. 7 | Buist AS, Thun MJ, Connell C, Jemal A, Lee TA, Miravitlles
108 II, 5. 8. 7 | Kunzli N, Leynaert B, Janson C, Gislason T, Vermeire P,
109 II, 5. 8. 7 | Gislason T, Vermeire P, Svanes C, Anto JM, Burney P (2004):
110 II, 5. 8. 7 | 125.~ ~Detournay B, Pribil C, Fournier M, Housset B,
111 II, 5. 8. 7 | Huas D, Godard P, Voinet C, Chanal I, Jourdanne C,
112 II, 5. 8. 7 | Voinet C, Chanal I, Jourdanne C, Durand-Zaleski I (2004):
113 II, 5. 8. 7 | 167: 418–424.~ ~Furhman C, Jougla E, Nicolauu J, Eilstein
114 II, 5. 8. 7 | Aine T, Bakke P, Janson C (2007): Mortality in COPD
115 II, 5. 8. 7 | Sobradillo V, Villasante C, Jimenez-Ruiz CA, Fernandez-Fau
116 II, 5. 8. 7 | RL, Middelboe T, Pisinger C, Stage KB (2004): Anxiety
117 II, 5. 8. 7 | Miravitlles M, de la Roza C, Morera J, Montemayor T,
118 II, 5. 8. 7 | Shepherd R, Kee F, Patterson C, MacMahon J (2005): Prevalence
119 II, 5. 8. 7 | McAuley S, Stewart A, Lamont C, Roseman P, Didsbury P (
120 II, 5. 8. 7 | Quesenberry CP Jr, DeLuise C, Lanes S, Eisner MD. COPD
121 II, 5. 8. 7 | S, Carrozzi L, Giuntini C (2000): Prevalence of airways
122 II, 5. 9. 7 | Bousquet PJ, Chinn S, Janson C, Kogevinas M, Burney P,
123 II, 5. 9. 7 | Jarvis D, Luczynska C, Chinn S, Potts J, Stunyer
124 II, 5. 9. 7 | Potts J, Stunyer J, Janson C, Svanec C, Kunzly N, (2005):
125 II, 5. 9. 7 | Stunyer J, Janson C, Svanec C, Kunzly N, (2005): Change
126 II, 5. 9. 7 | Bettoncelli G, Cricelli C, Sessa E, Mazzaglia G, Canonica
127 II, 5. 9. 7 | hcjz.hr~ ~Wang Y, McCusker C (2006): Neonatal exposure
128 II, 5. 10. 5 | Soybeans and products thereof (c)~- Milk and products thereof (
129 II, 5. 10. 5 | agent in beer and wine.~ ~(c) fully refined soybean oil
130 II, 5. 10. 7 | Cornelisse-Vermaat JR, Frewer L, Mills C, AEJ Dubois (2007): A framework
131 II, 5. 10. 7 | 1998.~Fasano A, Catassi C (2001): Current approaches
132 II, 5. 10. 7 | EN, Valovirta E, Madsen C, Taylor SL, Vieths S, Anklam
133 II, 5. 10. 7 | Beyer K, Frewer L, Madsen C, Botjes E, Crevel RWR, van
134 II, 5. 10. 7 | Rona R, Keil T, Summers C, Gislason D, Zuidmeer L,
135 II, 5. 10. 7 | Van Eckert R, Feighery C, Janssen FW, Méndez E, Mothes
136 II, 5. 10. 7 | Thomas K, Herouet-Guicheney C, Ladics G, Bannon G, Cockburn
137 II, 5. 10. 7 | R, Fitzpatrick J, Mills C, Privalle L, Vieths S (2007):
138 II, 5. 11. 3 | Point prevalence=3.6%~Mortz C, et al~Contact sensitisation~
139 II, 5. 11. 3 | yrs)~Prevalence=15%~Mortz C, et al~Hand eczema~Swedish
140 II, 5. 11. 3 | year prevalence=9%~Mortz C, et al~Psoriasis~Summary
141 II, 5. 11. 3 | might affect work ability (C Lidén et al, 2001). Moreover,
142 II, 5. 11. 3 | percentage of 25% in 1999 (C Lidén and K Norberg, 2005).
143 II, 5. 11. 3 | Dermatitis,1985;13:289–293.~C Lidén, M Bruze, T Menné,
144 II, 5. 11. 3 | Springer, 2001:935–950.~C Lidén, K Norberg, Nickel
145 II, 5. 11. 3 | 236.~SH Nguyen, TP Dang, C Macpherson, H Maibach, HI
146 II, 5. 11. 7 | University Press, 2003.~ ~Ceylan C, Ozturk G, Alper S (2003):
147 II, 5. 11. 7 | London: HMSO, 1986.~ ~Schmied C, Saurat JH (1991): Epidemiology
148 II, 5. 11. 7 | 2002;147:716-24.~ ~Wassberg C, Thorn M, Johansson AM et
149 II, 5. 12.Acr | Hepatitis B virus~HCV~Hepatitis C virus~ICD~International
150 II, 5. 12. 1 | disease, i.e., hepatitis B and C virus (HBV and HCV) infection
151 II, 5. 12. 4 | disease, i.e., hepatitis B and C virus (HBV and HCV) infection (
152 II, 5. 12. 7 | prevalence of hepatitis C virus infection in the United
153 II, 5. 12. 7 | past incidence of hepatitis C virus infection: implications
154 II, 5. 12. 7 | Hepatology 31:777-782.~ ~Bsetti C, Levi F, Lucchini F, Zatonski
155 II, 5. 12. 7 | WA, Negri E, La Vecchia C (2007): Worldwide mortality
156 II, 5. 12. 7 | combined action of hepatitis C virus infection and alcohol
157 II, 5. 12. 7 | 19:335-351.~ ~La Vecchia C, Levi F, Lucchini F, Franceschi
158 II, 5. 12. 7 | 4:480-486.~ ~La Vecchia C (2001): Alcohol in the Mediterranean
159 II, 5. 12. 7 | Boiocchi M, La Vecchia C, Franceschi S (2004): B-cell
160 II, 5. 12. 7 | s lymphoma and hepatitis C virus infection: a systematic
161 II, 5. 12. 7 | Boudjema K, Vanlemmens C, Mantion G, Messner M, Launois
162 II, 5. 12. 7 | epidemiology of hepatitis C virus infection. Lancet
163 II, 5. 14. 2 | teeth, dentures or gums?~ ~c. Periodontal Health Assessment~
164 II, 5. 14. 8 | Estupinan-Day S, N’Diaye C (2005): The global burden
165 II, 5. 15. 6 | Epub 2006 Jul 7.~McCabe C, Claxton K, Tsuchiya A (
166 II, 6.Acr | Infections~HCV~Hepatitis C Virus~HIB~Haemophilus Influenzae
167 II, 6. 3. 1 | Chlamydia infection, hepatitis C, toxoplasmosis, to name
168 II, 6. 3. 3 | addresses hepatitis B and C.~ ~Hepatitis B~ ~Hepatitis
169 II, 6. 3. 3 | most countries.~ ~Hepatitis C~ ~Hepatitis C is the most
170 II, 6. 3. 3 | Hepatitis C~ ~Hepatitis C is the most common type
171 II, 6. 3. 3 | in the E.U.~ ~Hepatitis C is caused by the hepatitis
172 II, 6. 3. 3 | caused by the hepatitis C virus (HCV), for which no
173 II, 6. 3. 3 | more than 29 000 hepatitis C cases were reported by 24
174 II, 6. 3. 5 | caused by serogroups B and C. Since 1999, several countries
175 II, 6. 3. 5 | programmes against serogroup C disease, using a new conjugated
176 II, 6. 3. 5 | introduction of the meningococcal C vaccine in high-risk populations.
177 II, 6. 4. 5 | of antimicrobial agents; c) make sure that antibacterial
178 II, 7. 4. 2 | these deaths (Figure 7.19.C). Injuries, at an advanced
179 II, 7. 4. 2 | are taken.~ ~Figure 7.19.c. Fatal injuries by causes
180 II, 7. 7 | 2008].~ ~Guo B, Harstall C (2004). For which strategies
181 II, 7. 7 | Health Organization.~ ~Körmer C, Smolka D (2008): Injuries
182 II, 7. 7 | F, Eriksson L, Tingvall C, Villaveces A (2004): Preventing
183 II, 7. 7 | Office for Europe.~ ~Todd C, Skelton D. (2004): What
184 II, 8. 2. 1 | Morrison, J., Melville, C. Finlayson, J., Allan, L.,
185 II, 8. 2. 1 | Emerson, E. and Hatton, C. (2007a). Contribution of
186 II, 8. 2. 1 | Emerson, E. and Hatton, C. (2007b). Poverty, socio-economic
187 II, 8. 2. 1 | Guidelines Limited.~Linehan, C., Walsh, P.N., et al., (
188 II, 8. 2. 1 | Lantman-de Valk HMJ, Linehan C, Kerr MP, Walsh PN (2007):
189 II, 8. 2. 1 | 47~Walsh, P.N., Linehan, C., Kerr, M., van Schrojenstein
190 II, 8. 2. 1 | Azema, B., Aussilloux, C., Määttä, T., Salvador-Carulla,
191 II, 8. 2. 1 | Kamper, M., Weber, G., Heiss, C., Haveman, M., Jørgensen,
192 II, 8. 2. 2 | Lopez AD, Mathers CD, Stein C (2001): The Global Burden
193 II, 8. 2. 2 | Available at: htt l.~Nucci C, Cedrone C, Culasso F, Ricci
194 II, 8. 2. 2 | Nucci C, Cedrone C, Culasso F, Ricci F, Cesareo
195 II, 8. 2. 3 | 33(6):395-402.~ ~Mathers C, Smith A, Concha M (2003):
196 II, 9. 1. 1 | condition-specific registers.~ ~ ~(C=core, R=recommended, F=for
197 II, 9. 1. 1 | development)~ ~Neonatal health~ C: Fetal mortality rate by
198 II, 9. 1. 1 | birth weight, plurality~C: Neonatal mortality rate
199 II, 9. 1. 1 | birth weight, plurality~C: Infant mortality rate by
200 II, 9. 1. 1 | birth weight, plurality~C: birth weight distribution
201 II, 9. 1. 1 | gestational age, plurality~C: Gestational age distribution
202 II, 9. 1. 1 | policies~Maternal health~ C: Maternal mortality ratio
203 II, 9. 1. 1 | characteristics/Risk factors~C: Multiple birth rate by
204 II, 9. 1. 1 | rate by number of fetuses~C: Distribution of maternal
205 II, 9. 1. 1 | Distribution of maternal age~C: Distribution of parity~
206 II, 9. 1. 1 | origin~Health care services~C: Distribution of births
207 II, 9. 1. 1 | Zhang W, Langer M, Vutuc C, Lindmark G (2003): Maternal
208 II, 9. 1. 1 | DiLallo D, Spadea T, Perucci C. Cesarean (1992): section
209 II, 9. 1. 1 | 111 Suppl 1:S45-52.~ ~Cans C, Guillem P, Fauconnier J,
210 II, 9. 1. 1 | Adams EK, Melvin CL, Kelsch C, Boulton ML (1999): Effects
211 II, 9. 1. 1 | Farine D, Saigal S, Nimrod C, Kelly E, et al (2002):
212 II, 9. 1. 1 | Hansen M, Kurinczuk JJ, Bower C, Webb S (2002): The risk
213 II, 9. 1. 1 | 3):451-7.~Platt MJ, Cans C, Johnson A, Surman G, Topp
214 II, 9. 1. 1 | Stephenson PA, Bakoula C, Hemminki E, Knudsen L,
215 II, 9. 1. 2 | in case of infant death c) the likelihood that an
216 II, 9. 1. 2 | sources of information.~ ~c) International Clearinghouse
217 II, 9. 1. 2 | order to ascertain survival c) greater accuracy and accessibility
218 II, 9. 1. 2 | even before pregnancy.~ ~c) Folic acid fortification
219 II, 9. 1. 2 | Botto LD, Lisi A, Bower C, Canfield MA, Dattani N,
220 II, 9. 1. 2 | MA, Dattani N, de Vigan C, de Walle H, Erickson EJ,
221 II, 9. 1. 2 | Robert-Gnansia E, Siffel C, Stoll C and Mastroiacovo
222 II, 9. 1. 2 | Robert-Gnansia E, Siffel C, Stoll C and Mastroiacovo P (2006): "
223 II, 9. 1. 2 | J, Steinbicker V, Roesch C, McDonnell R, Scarano G,
224 II, 9. 1. 2 | Dale I, Danaché B, De Vigan C, Fevotte J, Kiel G, Mandereau
225 II, 9. 1. 2 | Queisser-LuftA, de Vigan C, Addor M-C, Gener B, Haeusler
226 II, 9. 1. 2 | Jordan H, Tucker D, Stoll C, Feijoo M, Lillis D, Bianchi
227 II, 9. 1. 2 | MC, Botting B, de Vigan C, de Walle H, Garne E, Loane
228 II, 9. 1. 2 | Loane M, Dolk H, de Vigan C, Scarano G, Tucker D, Stoll
229 II, 9. 1. 2 | Scarano G, Tucker D, Stoll C et al (2005): “Prenatal
230 II, 9. 1. 2 | Garne E, Loane M, de Vigan C et al (2004): “Prenatal
231 II, 9. 1. 2 | no. 33.~Hansen M, Bower C, Milne E, de Klerk N, Kurinczuk
232 II, 9. 1. 2 | Lancet 338: 131-7.~Schaefer C, Garbis H, McElhatton P,
233 II, 9. 2. 7 | Alexander D, Rigby M, Hillger C, Neumann G, Kirch W (2008):
234 II, 9. 2. 7 | 1976.~ ~Levi F, La Vecchia C, Negri E, Lucchini F (2001):
235 II, 9. 2. 7 | Academy of Pediatrics~ ~Middle C, Johnson A, Alderdice F,
236 II, 9. 3. 1 | Communicable diseases~ ~Hepatitis C. In Western Europe the prevalence
237 II, 9. 3. 1 | EU enlargement, Hepatitis C was responsible for 30%
238 II, 9. 3. 1 | Boyle, P. Robertson, C. Mazzeha, C. Keech. M. Hobbs,
239 II, 9. 3. 1 | Robertson, C. Mazzeha, C. Keech. M. Hobbs, F.D.R.
240 II, 9. 3. 1 | Fourcade R. Kiemeney , L, Lee C. and the UrEpik Study Group (
241 II, 9. 3. 1 | Fenton K A and Lowndes C M (2004): Recent trends
242 II, 9. 3. 1 | Cancer Help UK (htt ~ ~Middle C, Johnson A, Alderdice F,
243 II, 9. 3. 2 | Zhang W, Langer M, Vutuc C, Lindmark G (2003): Maternal
244 II, 9. 3. 2 | DiLallo D, Spadea T, Perucci C. Cesarean (1992): section
245 II, 9. 3. 2 | 111 Suppl 1:S45-52.~ ~Cans C, Guillem P, Fauconnier J,
246 II, 9. 3. 2 | Adams EK, Melvin CL, Kelsch C, Boulton ML (1999): Effects
247 II, 9. 3. 2 | Farine D, Saigal S, Nimrod C, Kelly E, et al (2002):
248 II, 9. 3. 2 | Hansen M, Kurinczuk JJ, Bower C, Webb S (2002): The risk
249 II, 9. 3. 2 | 392-5).~ ~Platt MJ, Cans C, Johnson A, Surman G, Topp
250 II, 9. 3. 2 | Stephenson PA, Bakoula C, Hemminki E, Knudsen L,
251 II, 9. 3. 3 | the era of HIV, hepatitis C and other infections is
252 II, 9. 3. 3 | References~ ~Amaro F, Frazão C, Pereire ME, da Cunha Teles
253 II, 9. 3. 3 | Adolesc 28:535-40.~Currie C, Roberts C, Morgan A, Smith
254 II, 9. 3. 3 | 535-40.~Currie C, Roberts C, Morgan A, Smith R, Settertobultr
255 II, 9. 3. 3 | INI)). Official Journal C 271 E , 12/11/2003 P. 0369 -
256 II, 9. 3. 3 | federation of Finland.~Herlitz C, Ramstedt K (2005): Assessment
257 II, 9. 3. 3 | ckm014v1-7~Johnson A, Mercer C, Erens B, et al (2001):
258 II, 9. 3. 3 | Rundle K, Cousins G, Donnelly C, Mulcahy F, Conroy R (2006):
259 II, 9. 3. 3 | Rev 2:CD001035.~Signorelli C, Pasquarella C, Limina RM,
260 II, 9. 3. 3 | Signorelli C, Pasquarella C, Limina RM, Cozani E, Fanti
261 II, 9. 3. 3 | AM, Cpas AJ, Korovessis C, fenton KA, Fiels J (2001):
262 II, 9. 5. 6 | 15(12):2494-501~ ~Middle C, Johnson A, Alderdice F,
263 II, 9. 5. 6 | accessed 16.07.07)~ ~Paechter C (2003): Power, Bodies and
264 III, 10. 1. 3 | 10.1.3. References~Ambler C, Eliakim A, Brasel JA, Lee
265 III, 10. 1. 3 | LJ, Milligan R, Thompson C (1995): Assessment of nutrition
266 III, 10. 1. 3 | Gidding SS, Morgan W, Perry C, Isabel-Jones J, Bricker
267 III, 10. 1. 3 | Kayser B, Saris WHM, Pichard C (2005): Effects of physical activity
268 III, 10. 1. 3 | 885-895.~Meusel D, Höger C, Pérez-Rodrigo C, Cavill
269 III, 10. 1. 3 | Höger C, Pérez-Rodrigo C, Cavill N, Armstrong T,
270 III, 10. 1. 3 | Keller I, Riley L, Roy C, Tukuitonga C (2006): A
271 III, 10. 1. 3 | Riley L, Roy C, Tukuitonga C (2006): A framework to monitor
272 III, 10. 1. 3 | 49-61.~Parsons TJ, Power C, Logan S, Summerbell CD (
273 III, 10. 1. 3 | 205-8.~Tappy L, Binnert C, Schneiter Ph (2003): Energy
274 III, 10. 1. 3 | Wagner N, Meusel D, Höger C, Kirch W (2005): health promotion
275 III, 10. 2. 1 | tobacco_fr_en.pdf~ ~Bates C, Fagerström K, Jarvis MJ,
276 III, 10. 2. 1 | Kvinnsland S, La Vecchia C, Levi F, McVie JC, Maisonneuve
277 III, 10. 2. 1 | Richards M, Ringborg U, Scully C, Siracka E, Storm H, Tubiana
278 III, 10. 2. 1 | 2006; 25: 59-71~ ~Janson C, Künzli N, de Marco R, Chinn
279 III, 10. 2. 1 | Chinn S, Jarvis D, Svanes C, Heinrich J, Jõgi R, Gislason
280 III, 10. 2. 1 | M, Leynaert B, Luczynska C, Neukirch F, Vermeire P,
281 III, 10. 2. 1 | James M, Jefferson T, Lushey C, Morleo M, Stokes E, Sumnall
282 III, 10. 2. 1 | Campbell F, Schlesinger C, Heather N, Saunders J,
283 III, 10. 2. 1 | Hepatitis B Virus~HCV~Hepatitis C Virus~IDU~Injecting Drug
284 III, 10. 2. 1 | infected with hepatitis C virus in Europe. Regular
285 III, 10. 2. 1 | infected with the hepatitis C virus in Europe.~ ~
286 III, 10. 2. 1 | several countries. Hepatitis C infections among injecting
287 III, 10. 2. 1 | caused by the hepatitis C virus (HCV), is much more
288 III, 10. 2. 1 | Aids and hepatitis B and C) among drug users have triggered
289 III, 10. 2. 1 | problems, including hepatitis C and HIV/AIDS, as well as
290 III, 10. 2. 1 | Ketley CE, Van Loveren C, Seppa L, Cochran JA, Polido
291 III, 10. 2. 1 | Holbrook WP, van Loveren C, Fernandes B, Seppa L, Athanassouli
292 III, 10. 2. 1 | Estupinan-Day S, N’Diaye C. The global burden of oral
293 III, 10. 2. 1 | Dahlgren H, Holm AK, Kallestal C, Lagerlof F, Lingstrom P,
294 III, 10. 2. 1 | repository (see above).~ ~c) Reliable trend data~Bull
295 III, 10. 2. 1 | Pratt M, Macera CA, Blanton C (1999): Levels of physical activity
296 III, 10. 2. 1 | health-related behaviour. In: Currie C et al., eds. Young people’
297 III, 10. 2. 1 | and physical activity (OJ C 250 E, 25.10.2007, p. 93~·
298 III, 10. 2. 1 | Swedish).~ ~Bendixen H, Holst C, Sørensen TIA, Raben A,
299 III, 10. 2. 1 | October 2007).~ ~Bromley C, Sproston K, Shelton N,
300 III, 10. 2. 1 | October 2007).~ ~Bromley C, Sproston K, Shelton N,
301 III, 10. 2. 1 | 320:1240–1243.~ ~Currie C, Roberts C, Morgan A, Smith
302 III, 10. 2. 1 | 1243.~ ~Currie C, Roberts C, Morgan A, Smith R, Settertobulte
303 III, 10. 2. 1 | Dolman R, Kingdon A, Roberts C, eds (2007): Welsh Health
304 III, 10. 2. 1 | 2007).~ ~Elgar FJ, Roberts C, Tudor-Smith C, Moore L (
305 III, 10. 2. 1 | Roberts C, Tudor-Smith C, Moore L (2005): Validity
306 III, 10. 2. 1 | Nic Gabhainn S, Kelleher C (1999): The national health
307 III, 10. 2. 1 | E, Apolone G, La Vecchia C (2006): Overweight and obesity
308 III, 10. 2. 1 | Jackson-Leach R, nì Mhurchu C, Kalamara E, Shayeghi M,
309 III, 10. 2. 1 | Shayeghi M, Rigby NJ, Nishida C, Rodgers A (2004): Overweight
310 III, 10. 2. 1 | Report 54:1-11.~ ~Kelleher C, Gabhainn SN, Friel S, Corrigan
311 III, 10. 2. 1 | Publique 49:33-40.~ ~Padez C, Fernandes T, Mourão I,
312 III, 10. 2. 1 | Biology 16:670-678.~ ~Power C (1994): Health and social
313 III, 10. 2. 1 | Epiphaniou-Savva M, Chadjigeorgiou C, Kafatos A (2002): Obesity
314 III, 10. 2. 1 | Tornaritis M, Chadjigeorgiou C, Kourides YA, Savva ME,
315 III, 10. 2. 1 | Bartrina J, Pérez Rodrigo C, Saavedra Santana P, Peña
316 III, 10. 2. 1 | October 2007).~ ~Summerbell C, Waters E, Edmunds LD, Kelly
317 III, 10. 2. 1 | Europe 22(1):1-8.~ ~Gennari C (2001): Calcium and vitamin
318 III, 10. 2. 1 | Miller AB, Kroke A, Bamia C, Karalis D, Vineis P, Palli
319 III, 10. 2. 1 | D, Hjartaker A, Navarro C, Martinez GC, Wallstrom
320 III, 10. 2. 1 | Welch AA, Spencer E, Stripp C, Overvad K, Clavel-Chapelon
321 III, 10. 2. 1 | Clavel-Chapelon F, Casagrande C, Riboli E (2002): Consumption
322 III, 10. 2. 1 | X, Berrino F, Sacerdote C, Ocke MC, Peeters PH, Engeset
323 III, 10. 2. 1 | PH, Mulligan AA, Navarro C, Slimani N, Mattisson I,
324 III, 10. 2. 1 | Tumino R, Navarro Sanchez C, Martinez Garcia C, Mattisson
325 III, 10. 2. 1 | Sanchez C, Martinez Garcia C, Mattisson I, Nilsson S,
326 III, 10. 2. 1 | Naska A, Sieri S, Sacerdote C, Ocke MC, Peeters PH, Skeie
327 III, 10. 2. 1 | K, Tjonneland A, Stripp C, Clavel-Chapelon F, Kesse
328 III, 10. 2. 1 | Masala G, Tumino R, Sacerdote C, Del Pezzo M, Bueno-de-Mesquita
329 III, 10. 2. 1 | Boeing H, Kolyva M, Saieva C, Celentano E, Ocke MC, Peeters
330 III, 10. 2. 1 | M, Rodriguez M, Lasheras C, Janzon L, Jansson J, Luben
331 III, 10. 2. 4 | Dahm S, Nürnberg P, Roe C, Johnson J, Cox N J, Wichmann
332 III, 10. 2. 4 | Lewis JJ, Cordon-Cardo C (2001): Validation of tissue
333 III, 10. 2. 4 | Ibarreta D, Bock, A.K., Klein C, Rodriguez-Cerezo E (2003):
334 III, 10. 2. 4 | Leaderer B, Lai A, Spink C, Davis S, Bosch R, Scarpa
335 III, 10. 2. 4 | Sookoian SC, Gonzalez C, Pirola CJ (2005): Meta-analysis
336 III, 10. 2. 4 | 2131.~ ~Torhorst J, Bucher C, Kononen J, Haas P, Zuber
337 III, 10. 2. 5 | JP, Porter M, McFarland C (2007): The relation of
338 III, 10. 2. 5 | 39.~ ~Barker DJP, Osmond C, Forsén TJ, Kajantie E,
339 III, 10. 2. 5 | 71.~ ~Eriksson JG, Osmond C, Kajantie E, Forsén TJ,
340 III, 10. 2. 5 | Madigan S, Moran G, Schuengel C (2007): Unresolved maternal
341 III, 10. 2. 5 | S, Roberts R, Cox A, Day C (2002) The European Early
342 III, 10. 2. 5 | Wahlbeck K, Forsen T, Osmond C, Barker D, Eriksson J (2001):
343 III, 10. 3. 1 | Mäkeläinen I, Muirhead C, Oberaigner W, Pershagen
344 III, 10. 3. 1 | Prüss-Üstün A, Zeeb H, Mathers C, RepacholiM (Eds.). Solar
345 III, 10. 3. 2 | Forum. See: htt ~ ~Barbante C, et al (1999). Greenland
346 III, 10. 3. 2 | Gomez, G Morrison, S Rauch, C McLeod, R Ma, S Caroli,
347 III, 10. 3. 2 | P Schramel, M Zischka, C Pettersson, U Wass, M Luna,
348 III, 10. 4. 2 | spongiform encephalopathies; c) food hygiene: assure consistency
349 III, 10. 4. 2 | requiring rapid action; (c) any rejection, related
350 III, 10. 4. 2 | modified organisms (mainly Part C thereof);~· The placing
351 III, 10. 4. 2 | any conflict of interest; (c) that adequate laboratory
352 III, 10. 4. 2 | and responsibilities; and (c) the channels and procedures
353 III, 10. 5. 1 | Mccarthy H, Oren R, Finzi C, EllsWorth DS, Jonshen KH,
354 III, 10. 5. 1 | University Press) Oxford.~Michaud C, Murray C, Bloom B (2001):
355 III, 10. 5. 1 | Oxford.~Michaud C, Murray C, Bloom B (2001): Burden
356 III, 10. 5. 3 | Session 2006, Report I (C). ILO, Geneva. Available
357 III, 10. 6. 1 | 9): 1442-1445.~ ~Currie C, Gabhainn S, Godeau E, Roberts
358 III, 10. 6. 1 | Gabhainn S, Godeau E, Roberts C, Smith R, Currie D, Picket
359 III, 10. 6. 2 | Dalstra JAA, Kunst AE, Borrell C, Breeze E, Cambois E, Costa
360 IV, 11. 1. 3 | systems with social insurance; c) separating purchasing from
361 IV, 11. 5. 4 | HIV/AIDS, hepatitis B and C, bacteria, fungi and parasites
362 IV, 11. 6. 5 | Barer ML, Evans RG, Hertzman C, Lomas J. (1987): "Aging
363 IV, 11. 6. 5 | Malone J, Rüther A, Wild C. Best practice in undertaking
364 IV, 11. 6. 5 | 153: 1715-19.~ ~Castoro C, Bertinato L et al. (2007):
365 IV, 11. 6. 5 | Policies.~ ~Chaix-Couturier C, Durand-Zaleski I et al. (
366 IV, 11. 6. 5 | Durieux P, Chaix-Couturier C et al. (2000): "From clinical
367 IV, 11. 6. 5 | Press.~ ~Hutton J, McGrath C et al. (2006): "Framework
368 IV, 11. 6. 5 | Saltman, J. Figueras and C. Sakellarides. Buckingham,
369 IV, 11. 6. 5 | 22(3): 134-48.~ ~Masseria C, Koolman X et al. (2004):
370 IV, 11. 6. 5 | Quarterly 62(4): 591-608.~ ~Shaw C (2003): How can hospital
371 IV, 11. 6. 5 | 3(2): 80-95.~ ~Sorenson C, Kanavos P et al. (2007):
372 IV, 11. 6. 5 | van Doorslaer E, Masseria C et al. (2004): Income-related
373 IV, 12. 1 | protection of public health;~(c) incentive measures designed
374 IV, 12. 10 | 2006 Campaign: FA C T S A N D A D V I C E~about
375 IV, 12. 10 | FA C T S A N D A D V I C E~about smoking and stopping~http df~
376 IV, 12. 10 | workplaces and at meetings.~C. “GetMoving” is an annual
377 IV, 12. 10 | sozialen Brennpunkten E&C) htt ; In cooperation with
378 IV, 12. 10 | delivered and managed.~ ~ ~ ~C) OTHER INFORMATION ON NATIONAL
379 IV, 12. 10 | diseases (i.e. Hepatitis B & C, HPV, Syphilis, and Gonorrhea).
|
|
| |
